title: [Antibiotic resistance of Helicobacter pylori in Reunion Island: therapeutic consequences].
abstract: The aims of this paper were to assess resistance of Helicobacter pylori to antibiotics included in the so-called French triple regimens and to identify the possible causes of therapeutic failure in Reunion island. Antibiotic resistance was determined for 109 strains. All the strains were sensitive to amoxicillin and tetracycline, 93.6% were sensitive to ciprofloxacin, 92.7% to erythromycin and 60.6% to metronidazole. Fifty three patients who had previously tested positive for H. pylori received for one week regimen of amoxicillin (1 g bd), clarithromycin (0.5 g bd) and omeprazole (20 mg bd). Eradication rate after therapy was of 73.6%. Therapeutic failure was analysed for 9 patients using random amplified polymorphic DNA and the presence or not of antibiotic resistance. One cause of failure is clarithromycin resistance. These data show that triple therapy can be used in Reunion Island. In case of failure, sensitivity must be detected because the rate of resistance to metronidazole is over 30%.
authors.affiliation: Laboratoire de bactériologie parasitologie virologie, Groupe hospitalier Sud Réunion, BP 350, 97448 Saint Pierre, La Réunion, France.
authors.forename: S
authors.initials: S
authors.lastname: Picot
authors.forename: G
authors.initials: G
authors.lastname: Sapin
authors.forename: A
authors.initials: A
authors.lastname: Michault
authors.forename: B
authors.initials: B
authors.lastname: Faulques
authors.forename: J P
authors.initials: JP
authors.lastname: Becquart
authors.forename: C
authors.initials: C
authors.lastname: Simac
authors.forename: C
authors.initials: C
authors.lastname: Amat
authors.forename: E
authors.initials: E
authors.lastname: Ancelin-Malbreil
mesh_terms: D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D016009:Chi-Square Distribution; D002939:Ciprofloxacin / Q000627:therapeutic use; D017291:Clarithromycin / Q000627:therapeutic use; D016001:Confidence Intervals; D004269:DNA, Bacterial / Q000032:analysis; D024881:Drug Resistance, Bacterial / Q000235:genetics; D004917:Erythromycin / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D010406:Penicillins / Q000627:therapeutic use; D019105:Random Amplified Polymorphic DNA Technique; D017508:Reunion; D013276:Stomach Ulcer / Q000188:drug therapy / Q000382:microbiology*; D013752:Tetracycline / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D004269:DNA, Bacterial; D010406:Penicillins; D008795:Metronidazole; D002939:Ciprofloxacin; D004917:Erythromycin; D000658:Amoxicillin; D013752:Tetracycline; D017291:Clarithromycin; D009853:Omeprazole